ReviewCurrent diabetes reports2017
Cell Therapy for Type 1 Diabetes: Current and Future Strategies.
Review in Current diabetes reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Personalized medicine as a novel therapeutic approach for autoimmune diseases: new insights and future prospects.Osong public health and research perspectives · 2026Article
- LINC MIR503HG Controls SC-β Cell Differentiation and Insulin Production by Targeting CDH1 and HES1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Hydrogel-based Drug Delivery System in Diabetes Management.Pharmaceutical nanotechnology · 2024Review
- Review
- NEUROD2 function is dispensable for human pancreatic β cell specification.Frontiers in endocrinology · 2023Article
- Sustained heterologous gene expression in pancreatic islet organoids using adeno-associated virus serotype 8.Frontiers in bioengineering and biotechnology · 2023Article
- Fabrication of nanofibrous mat surrounded hydrogel scaffold as an encapsulation device for encapsulating pancreas β cells.Scientific reports · 2022Article
- Spleen extracellular matrix provides a supportive microenvironment for β-cell function.Iranian journal of basic medical sciences · 2022Article
- Pancreatic transplant surgery and stem cell therapy: Finding the balance between therapeutic advances and ethical principles.World journal of stem cells · 2022Review
- Differential Function and Maturation of Human Stem Cell-Derived Islets After Transplantation.Stem cells translational medicine · 2022Article
- Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.Endocrine reviews · 2022Review
- Biomaterials for Cell-Surface Engineering and Their Efficacy.Journal of functional biomaterials · 2021Review
- Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment.World journal of diabetes · 2020Review
- Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes.Nature communications · 2019Article
- Non-invasive delivery strategies for biologics.Nature reviews. Drug discovery · 2019Review
- Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.Current diabetes reports · 2018Review
- FGF-2b and h-PL Transform Duct and Non-Endocrine Human Pancreatic Cells into Endocrine Insulin Secreting Cells by Modulating Differentiating Genes.International journal of molecular sciences · 2017Article
- Bio-Engineering of Pre-Vascularized Islet Organoids for the Treatment of Type 1 Diabetes.Transplant international : official journal of the European Society for Organ TransplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewType 1 diabetes (T1D) is defined by an autoimmune destruction of insulin producing β-cells located in the endocrine part of the pancreas, the islets of Langerhans. As exogenous insulin administration fails at preventing severe complications associated with this disease, cell replacement therapies are being considered as a means to treat T1D. The purpose of this manuscript is to review the challenges associated with current strategies and discuss the potential of stem cell therapy for the treatment of T1D. RECENT
findingsThe most prominent therapy offered to T1D patients is exogenous insulin administration which, despite formulations improvement, remains a suboptimal treatment, due to the frequency of injections and the issues associated with precise dosing. As immunotherapy approaches have remained unsuccessful, the only cure for T1D is transplantation of donor-derived pancreas or islets. However, donor scarcity, graft loss, and immune response to the foreign tissue are issues challenging this approach and limiting the number of patients who can benefit from such treatments. In this review, we discuss the causes of T1D and the shortcomings of the current treatments. Furthermore, we summarize the cutting edge research that aims to tackle the current challenges in reaching a quality-controlled product with long-term effects, with a focus on regenerative medicine approaches using human pluripotent stem cells.
Indexed as
Identifiers
28432571What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.